ACE2-generated small peptide shows promise in clear-cell kidney cancer

Reuters Health - 27/01/2021 - Angiotensin-(1-7), a small peptide generated by angiotensin-converting enzyme 2 (ACE2), shows promise in combination with a programmed death-ligand 1 (PD-L1) pathway inhibitor and a vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI) for patients with clear cell renal cell carcinoma (ccRCC), a preclinical study suggests. Although the standard of care of metastatic RCC is combined VEGF/PD-1 pathway inhibition, "resistance is a key unmet need, and means to improve this could easily translate to clinical trials," Drs. Thomas Walther of University College Cork, Ireland, and Rupal Bhatt of Beth Israel Deaconess Medical Center in Boston told Reuters Health in a joint email. In a series of preclinical experiments in mouse models and tumor cells published in Science Translational Medicine, the team showed: - ACE2 expression correlates strongly with overall survival in ccRCC patients. - Higher ACE2 exp...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 27 January, 20218 February, 2021